Chemical Structure : TMQ0153
货号: PC-24387Not For Human Use, Lab Use Only.
TMQ0153 (TMQ153) is a tetrahydrobenzimidazole derivative with cytotoxic potential against hematopoietic cancer cell lines, targets mitochondrial dynamics by inhibiting mitochondrial fusion protein optic atrophy 1 (OPA1), inducing metabolic reprogramming, and triggering apoptosis in AML cells.
大包装,大折扣!
E-mail: sales@probechem.com
Tech Support: tech@probechem.com
TMQ0153 (TMQ153) is a tetrahydrobenzimidazole derivative with cytotoxic potential against hematopoietic cancer cell lines, targets mitochondrial dynamics by inhibiting mitochondrial fusion protein optic atrophy 1 (OPA1), inducing metabolic reprogramming, and triggering apoptosis in AML cells.
TMQ0153 inhibits cell viability, proliferation and colony formation capacity of drug-sensitive and -resistant cancer cells.
TMQ0153 triggers a concentration-dependent induction of caspase-dependent and independent non-apoptotic cell death in K562 cells.
TMQ0153 activates necrostatin-1 sensitive necroptotic cell death.
TMQ0153 stimulates autophagy prior to necroptosis.
TMQ0153 depolarizes mitochondrial membrane potential and triggers necroptotic cell death through ROS formation.
TMQ0153 treatment significantly reduced OPA1 and mitofusin (MFN)2 protein levels and disrupted the mitochondrial morphology and function in AML cells.
TMQ0153 treatment reduces tumor volume and weight in MV4-11 xenografts in vivo.
分子量 | 276.72 | |
分子式 | C14H13ClN2O2 | |
外观性状 | Solid | |
储存条件 |
|
|
Solubility |
10 mM in DMSO |
1. Song S, et al. Cell Death Dis. 2020 Feb 7;11(2):109.
2. Park SJ, et al. J Exp Clin Cancer Res. 2025 Apr 7;44(1):114.
3. Tran MQ, et al. Eur. J. Org. Chem. 2018;2018:5878–5884.
备案号:沪ICP备16042516号-1 Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright